(Q36661844)

15 August 2017

1 reference

title

Prophylaxis in haemophilia patients with inhibitors (English)

1 reference

15 August 2017

0 references

Leissinger CA

1

1 reference

15 August 2017

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

12 Suppl 6

1 reference

15 August 2017

page(s)

67-72; discussion 72-3

1 reference

Radiological and orthopedic score in pediatric hemophilic patients with early and late prophylaxis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Immune tolerance induction in hemophilia A: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Clinical outcomes and resource utilization associated with haemophilia care in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Surgery in haemophilic patients with inhibitor: 20 years of experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Immune tolerance: a synopsis of the international experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

The economic impact of factor VIII inhibitors in patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2006.01369.X

10.1111/J.1365-2516.2006.01369.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference